Navigation Links
Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

Studies of people with acquired immunodeficiency syndrome (AIDS) have reported increased risks of several cancers, including Kaposi sarcoma, non-Hodgkin lymphoma, and, to a lesser extent, anal cancer, invasive cervical cancer, and Hodgkin lymphoma. However, less well understood are the associations of these cancer risks with the use of HAART, with immune status, and with behavioral risk factors such as smoking.

To estimate excess cancer risk in people infected with HIV and investigate the modifying effects of the use of HAART and behavioral factors on this cancer risk, Gary M. Clifford, Ph.D., of the International Agency for Research on Cancer in Lyon, France, and colleagues analyzed data from the Swiss HIV Cohort Study and Swiss cancer registries on more than 7,300 people infected with HIV.

People with HIV in the study had a highly elevated risk of Kaposi sarcoma and non-Hodgkin lymphoma. They also had an increased risk of anal cancer, Hodgkin lymphoma, cervical cancer, liver cancer, cancer of the lip, mouth, and pharynx, and non-melanoma skin cancer. People who used HAART had lower risks of Kaposi sarcoma and non-Hodgkin lymphoma compared with those who did not use HAART, although even with HAART these tumors occurred 20 times more frequently than they do in the general population without HIV/AIDS. HAART use was not associated with lower risks of Hodgkin lymphoma or other cancers. Although people infected with HIV had increased risks of cancers of the lung, lip, mouth, and pharynx, no cases of these cancers were found among nonsmokers.

"In conclusion, HAART treatment may prevent excess risk of [Kaposi sarcoma] and non-Hodgkin lymphoma, but not that of Hodgkin lymp homa or other non–AIDS-defining cancers," the authors write. "Focusing on ways to encourage persons infected with HIV to quit smoking would be effective in reducing lung cancer in these persons."

In an editorial, Eric A. Engels, M.D., and James J. Goedert, M.D., of the National Cancer Institute, revisit the history of the AIDS epidemic and how the knowledge of cancer and immune diseases has grown since it began. They note that questions remain about the types and severity of cancers that will appear in coming years among patients on HAART, who have less severe but prolonged immunosuppression. "Controlling the epidemic and ameliorating the suffering of persons living with HIV/AIDS are more urgent than ever," they write. "Continued study of cancer in people with HIV/AIDS will redound to give us clues about cancer etiology to the benefit of all."

Citations:
# Article: Clifford GM, Polesel J, Rickenbach M on behalf of the Swiss HIV Cohort Study, Dal Maso L, Keiser O, Kofler A, et al. Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy. J Natl Cancer Inst 2005;97:425?2.

# Editorial: Engels EA, Goedert JJ. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Cancer: Past, Present, and Future. J Natl Cancer Inst 2005;97:407?.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Antiretroviral Therapy May Prevent HIV Transmission From Breastfeeding Mothers To Infants
2. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
3. Columbia research lifts major hurdle to gene therapy for cancer
4. Combination therapy boosts effectiveness of telomere-directed cancer cell death
5. Gene therapy converts dead bone graft to new, living tissue
6. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
9. New therapy for HIV/AIDS eliminates needles and excessive toxicity
10. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
11. Gene therapy for Parkinsons disease moves forward in animals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... (PRWEB) , ... August 18, 2020 , ... ... to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) ... Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this ...
(Date:8/12/2020)... , ... August 12, 2020 , ... ... monitoring systems that are ideal for public health agencies of all sizes. With ... diseases and helping at-risk individuals find appropriate health care, Mosio helps public health ...
(Date:7/31/2020)... ... 2020 , ... BioFactura, Inc. today announced a $1 million ... & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). ... efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, ... that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , ... or two switches in a push-pull configuration; yielding fast fall time for a ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
Breaking Biology Technology: